Filtered By:
Cancer: Breast Cancer
Drug: Coreg
This page shows you your search results in order of date.
Order by Relevance | Date
Total 644 results found since Jan 2013.
Comparative Evaluation of Captopril, Spironolactone, and Carvedilol Effect on Endothelial Function in Breast Cancer Women Undergoing Chemotherapy
CONCLUSION: Prescribing combination of Carvedilol, Spironolactone, and Captopril in breast cancer patients undergoing chemotherapy can improve endothelial function and may have beneficial effects on diastolic function.PMID:37434915 | PMC:PMC10331532 | DOI:10.4103/abr.abr_81_21
Source: Biomed Res - July 12, 2023 Category: Research Authors: Seyed Mohammad Hashemi Jazi Faranak Tayebi Zahra Teimouri-Jervekani Fariborz Mokarian Valiallah Mehrzad Alireza Sadeghi Source Type: research
Evaluation of the Effect of Carvedilol in Preventing Right Ventricular Dysfunction in Breast Cancer Patients Receiving Anthracycline
CONCLUSION: According to the results of the present study, the effect of using carvedilol as a preservative on improving RV function was seen compared to the control group, although this difference was not statistically significant.PMID:36926423 | PMC:PMC10012032 | DOI:10.4103/abr.abr_134_21
Source: Cancer Control - March 17, 2023 Category: Cancer & Oncology Authors: Mersede Karvandi Mojtaba Ghadyani Nahid Mohebbi Mehdi Tabarraee Sina Salari Source Type: research
Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice
CONCLUSION: CAR could be used as an adjuvant therapy with DOX, especially when nanoformualted with PLGA and even better with Niosomes, without compromising its cytotoxicity against cancer cells and preventing its cardiotoxic impacts.PMID:36921847 | DOI:10.1016/j.taap.2023.116448
Source: Toxicology and Applied Pharmacology - March 15, 2023 Category: Toxicology Authors: Amr Zidan Amira A El Saadany Gamal M El Maghraby Amany A Abdin Sabeha E Hedya Source Type: research
The role of ARID1A in the non-estrogenic modulation of IGF-1 signaling
This study underscores the possibility of the pharmacologic modulation of the ARID1A factor to down-regulate pro-tumorigenic IGF-1 activity in postmenopausal breast cancer patients undergoing aromatase inhibitor treatment.PMID:35320351 | DOI:10.1158/1541-7786.MCR-21-0961
Source: Cell Research - March 23, 2022 Category: Cytology Authors: Sham Jdeed Edina Erdos Balint Laszlo Balint Ivan P Uray Source Type: research
Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma
CONCLUSION: Carvedilol at a daily dose of 12.5mg has a protective effect against diastolic disorder and at a daily dose of 25mg has a protective effect against both systolic and diastolic disorders.PMID:24839645 | DOI:10.15420/ahhj.2011.9.2.95
Source: The American Heart Hospital Journal - May 20, 2014 Category: Cardiology Authors: Rezvanie Salehi Bijan Zamani Ali Esfehani Samad Ghafari Mohsen Abasnezhad Mohamad Goldust Source Type: research
